Born in Reading, England, Andrew gained his MChem degree in medicinal chemistry in 2010 at Newcastle University, UK, working with Professor Mike North on the use of cyclic carbonates as environmentally friendly solvents for  Friedel-Crafts acylations. During this time, he worked at GlaxoSmithKline, Stevenage, on the design of bromodomain inhibitors for inflammatory disease therapy, and has since worked at contract organic synthesis firms Onyx Scientific Ltd, Sunderland and NewChem Technologies Ltd, Newcastle-Upon-Tyne.

 

Andrew achieved his PhD in 2014 at Newcastle University, UK, working with Professor Roger John Griffin on the design and synthesis of novel small-molecule protein-protein interaction inhibitors for cancer treatment, targeting the SCFSKP2 E3 Ligase complex and the p53-MDMX interaction.

 

His current research aims to design potent small-molecule inhibitors of STAT3:STAT3 dimerization for cancer therapy with optimized pharmacokinetics and toxicity profiles.